Irbesartan

Contraindicated

Irbesartan Aliskiren Tekturna An increased risk of hyperkalemia, renal impairment, and hypotension Details Irbesartan Sparsentan Filspari An increased risk of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure), reduced CY... Details

Major

Irbesartan Lisinopril Prinivil Increased risk of adverse events (ie, hypotension, syncope, hyperkalemia, changes in renal function, acute renal failure) Details Irbesartan Benazepril Lotensin Increased risk of adverse events (ie, hypotension, syncope, hyperkalemia, changes in renal function, acute renal failure) Details Irbesartan Capecitabine Xeloda Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Irbesartan Captopril Capoten® Increased risk of adverse events (ie, hypotension, syncope, hyperkalemia, changes in renal function, acute renal failure) Details Irbesartan Cyclosporine Injection Atopica An increased risk of hyperkalemia Details Irbesartan Cyclosporine Ophthalmic Cequa An increased risk of hyperkalemia Details Irbesartan Digoxin Cardoxin® An increased digoxin exposure Details Irbesartan Enalapril Epaned Increased risk of adverse events (ie, hypotension, syncope, hyperkalemia, changes in renal function, acute renal failure) Details Irbesartan Entacapone Comtan Increased exposure of CYP2C9 substrate Details Irbesartan Fluorouracil Adrucil Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Irbesartan Fluorouracil Injection Adrucil Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Irbesartan Fluorouracil Topical Carac Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Irbesartan Fosinopril Monopril® Increased risk of adverse events (ie, hypotension, syncope, hyperkalemia, changes in renal function, acute renal failure) Details Irbesartan Furosemide Injection Disal Severe hypotension and deterioration in renal function, including renal failure Details Irbesartan Apalutamide Erleada Reduced CYP2C9 substrates exposure Details Irbesartan Carbamazepine Carbatrol Reduced CYP2C9 substrate exposure and reduced efficacy of CYP2C9 substrate Details Irbesartan Ceritinib Zykadia Increased exposure of CYP2C9 substrate Details Irbesartan Cilazapril Increased risk of adverse events (ie, hypotension, syncope, hyperkalemia, changes in renal function, acute renal failure) Details Irbesartan Cyclosporine Atopica An increased risk of hyperkalemia Details Irbesartan Deutivacaftor Increased CYP2C9 substrate exposure Details Irbesartan Doxifluridine Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Irbesartan Enalaprilat Increased risk of adverse events (ie, hypotension, syncope, hyperkalemia, changes in renal function, acute renal failure) Details Irbesartan Fluconazole Diflucan Increased angiotensin II blocker exposure and an increased risk of toxicity Details Irbesartan Furosemide Disal Severe hypotension and deterioration in renal function, including renal failure Details Irbesartan Insulin Icodec-Abae Awiqli An increased risk of hypoglycemia Details Irbesartan Lithium Increased risk of lithium toxicity Details Irbesartan Loperamide Diamode An increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Irbesartan Moexipril Univasc® Increased risk of adverse events (ie, hypotension, syncope, hyperkalemia, changes in renal function, acute renal failure) Details Irbesartan Paclitaxel Abraxane Increased PACLitaxel exposure Details Irbesartan Paclitaxel Protein-Bound Increased PACLitaxel exposure Details Irbesartan Perindopril Aceon Increased risk of adverse events (ie, hypotension, syncope, hyperkalemia, changes in renal function, acute renal failure) Details Irbesartan Phenobarbital Fidoquel Reduced CYP2C9 substrate exposure and reduced efficacy of CYP2C9 substrate Details Irbesartan Potassium Citrate Urocit-K Increased risk of hyperkalemia Details Irbesartan Potassium Phosphate K-Phos Increased risk of severe and potentially fatal hyperkalemia Details Irbesartan Primidone Mysoline Reduced CYP2C9 substrate exposure and reduced efficacy of CYP2C9 substrate Details Irbesartan Quinapril Accupril Increased risk of adverse events (ie, hypotension, syncope, hyperkalemia, changes in renal function, acute renal failure) Details Irbesartan Ramipril Altace Increased risk of adverse events (ie, hypotension, syncope, hyperkalemia, changes in renal function, acute renal failure) Details Irbesartan Sacubitril Increased risk of adverse events Details